<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012451910</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012451910</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Concentrations of Diazepam and Nordiazepam in 1000 Blood Samples From Apprehended Drivers—Therapeutic Use or Abuse of Anxiolytics?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jones</surname>
<given-names>Alan W.</given-names>
</name>
<degrees>PhD, DSc</degrees>
<xref ref-type="aff" rid="aff1-0897190012451910">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190012451910"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Holmgren</surname>
<given-names>Anita</given-names>
</name>
<xref ref-type="aff" rid="aff1-0897190012451910">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0897190012451910">
<label>1</label>Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden</aff>
<author-notes>
<corresp id="corresp1-0897190012451910">Alan W. Jones, Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Artillerigatan 12, Linköping 58758, Sweden. Email: <email>wayne.jones@rmv.se</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>26</volume>
<issue>3</issue>
<issue-title>Pharmacy Practice I</issue-title>
<fpage>198</fpage>
<lpage>203</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Using an in-house forensic toxicology database, we selected 1000 cases of driving under the influence of drugs (DUIDs) over a 12-month period if diazepam (D) and nordiazepam (ND) were both present in the blood samples. Quantitative analysis of D and ND in blood was done by solvent extraction (butyl acetate) and capillary column gas chromatography (GC) with a nitrogen–phosphorous (N-P) detector. The limits of quantitation of this analytical method for D and ND in blood were 0.05 mg/L. The correlation between D and ND concentrations in blood was statistically significant (<italic>r</italic> = .58, <italic>P</italic> &lt; .001), as expected for a parent drug and its primary metabolite. However, the frequency distributions were markedly skewed to the right with mean (median) and highest concentrations of 0.37 (0.20) and 6.1 mg/L for D and 0.39 (0.20) and 5.6 mg/L for ND. The mean (median) total concentration (D + ND) was 0.76 mg/L (0.50 mg/L), and the concentration ratios D/ND and ND/D were 1.29 (median 0.95) and 1.41 (median 1.06), respectively. In 90 cases (9%), the concentration of D in blood exceeded 0.83 mg/L, which corresponds to an upper therapeutic limit in plasma (∼1.5 mg/L), assuming a plasma/blood distribution ratio of 1.8:1.</p>
</abstract>
<kwd-group>
<kwd>analysis</kwd>
<kwd>blood</kwd>
<kwd>diazepam</kwd>
<kwd>driving</kwd>
<kwd>impairment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012451910">
<title>Introduction</title>
<p>Several European nations enforce zero-tolerance or zero-limit laws for driving under the influence of drugs (DUIDs) included in the list of controlled substances.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012451910">1</xref>
<xref ref-type="bibr" rid="bibr2-0897190012451910"/>–<xref ref-type="bibr" rid="bibr3-0897190012451910">3</xref>
</sup> This new type of drug per se law simplifies prosecution of impaired drivers by making it an offence to drive with any measurable amount of an illicit drug in blood. However, additional evidence is necessary to prosecute a driver who takes a scheduled prescription drug, such as opiate pain medication or sedative-hypnotics, before driving.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012451910">4</xref>
<xref ref-type="bibr" rid="bibr5-0897190012451910"/>–<xref ref-type="bibr" rid="bibr6-0897190012451910">6</xref>
</sup> Such evidence might include the results of clinical tests of suspects that show deterioration of cognitive and/or psychomotor functioning.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012451910">7</xref>,<xref ref-type="bibr" rid="bibr8-0897190012451910">8</xref>
</sup> Alternatively, if the concentration of a scheduled prescription drug in blood is above the normal therapeutic level, this information might also be used to suggest abuse or overdosing with medication.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012451910">1</xref>,<xref ref-type="bibr" rid="bibr9-0897190012451910">9</xref>
</sup>
</p>
<p>Diazepam (D) is a class IV scheduled substance in Sweden and this benzodiazepine is widely prescribed for the treatment of anxiety disorder, as a sedative-hypnotic and an anticonvulsant and as such is often identified in blood samples from apprehended drivers.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012451910">4</xref>,<xref ref-type="bibr" rid="bibr9-0897190012451910">9</xref>
</sup> After oral administration, D is rapidly absorbed from the gut and its primary metabolite is <italic>N</italic>-desmethydiazepam (nordiazepam [ND]), which is also pharmacologically active.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012451910">10</xref>,<xref ref-type="bibr" rid="bibr11-0897190012451910">11</xref>
</sup> Both D and ND are depressants of the central nervous system and work by binding with γ-aminobutyric acid (GABA<sub>A</sub>) receptor complex which slows down brain activity, causing sedation.</p>
<p>Studies have shown that D and other benzodiazepines impair skills needed for safe driving and improper use of this medication is, therefore, a danger for traffic safety.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012451910">12</xref>,<xref ref-type="bibr" rid="bibr13-0897190012451910">13</xref>
</sup> ND is a metabolite of clorazepate, chlordiazepoxide, and parazepam,<sup>
<xref ref-type="bibr" rid="bibr14-0897190012451910">14</xref>
</sup> although these substances are not approved by the drug-regulating authorities in Sweden and, accordingly, are not available for purchase. This means that the presence of ND in blood samples, in this study, reflects intake of D before driving.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012451910">15</xref>
</sup>
</p>
<p>This study reports the concentrations of D and ND in 1000 blood samples from people arrested for impaired driving in Sweden. The aim of this study was to estimate how many individuals might have overdosed with anxiolytic medication, and this required a consideration of the plasma/blood distribution ratio of D.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012451910">16</xref>
</sup>
</p>
</sec>
<sec id="section2-0897190012451910" sec-type="methods">
<title>Methods</title>
<sec id="section3-0897190012451910">
<title>Apprehension of Offender</title>
<p>The population of Sweden is close to 9.3 million, and a zero-tolerance law for driving under the influence of illicit and scheduled prescription drugs was introduced in 1999. Since this law came into force, the number of blood samples submitted by the police for toxicological analysis has increased 12-fold. Blood specimens from all apprehended drivers in Sweden are sent for analysis to a central forensic toxicology laboratory. The results of the analytical toxicology along with demographics of offenders are entered into a national database (TOXBASE), which was used in this study.</p>
<p>The first suspicion of impaired driving arises from observations made by the police or other road users. After stopping a vehicle because of a moving traffic offence, involvement in a crash or as part of a routine control the driver is required to submit to a roadside breath alcohol (BAC) test. Probable cause to administer this roadside BAC test is not required by the police in Sweden. If the result of the BAC test is negative (BAC &lt;0.02 g/100 mL or 20 mg/100 mL) and the driver displays signs and symptoms of drug influence, then a blood sample is obtained for toxicological analysis.</p>
<p>Suspicion of being under the influence of drugs other than alcohol often depends on the person’s general appearance and behavior when questioned by the police or finding drug paraphernalia in the vehicle. The police officers are also allowed to examine the driver’s eyes and to observe pupil size and the presence of any nystagmus.</p>
</sec>
<sec id="section4-0897190012451910">
<title>Determination of D and ND in Blood</title>
<p>Blood specimens from apprehended drivers were subjected to a broad screening analysis for 5 classes of abused drugs (opiates, cannabinoids, amphetamine analogs, cocaine metabolite, and benzodiazepines). Proteins were precipitated with acetone and the drugs analyzed in supernatant with enzyme-multiplied immunoassay (EMIT) and cloned enzyme donor immunoassay (CEDIA) using an ADVIA 1650 instrument from Bayer Health Care Diagnostics. When results of the immunoassay screening analysis were positive, the blood specimens were reanalyzed using more specific analytical methods including gas chromatography–mass spectrometry (GC-MS) and liquid-chromatograph–mass spectrometry (LC-MS) for illicit drugs. This article is only concerned with the concentrations of D and ND in blood so other drugs if present are not considered.</p>
<p>After addition of internal standard (parazepam) to an aliquot of whole blood (1 mL), D, ND as well as other weakly acid, neutral and basic drugs were extracted by shaking vigorously with butyl acetate. After concentrating the solvent extract by evaporation, an aliquot was analyzed by capillary column GC with nitrogen–phosphorous (N-P) detector as described elsewhere.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012451910">16</xref>
</sup> The analytical limits of quantitation (LOQ) for determination of D and ND in blood by this GC-NPD method were 0.05 mg/L.</p>
</sec>
<sec id="section5-0897190012451910">
<title>Statistical Analysis</title>
<p>Frequency distributions of the concentrations of D and ND in blood were skewed to the right therefore as descriptive statistics median and upper percentile points were used. Two median concentrations were compared by the Mann-Whitney nonparametric test and the Pearson correlation coefficient was calculated as a measure of strength of association, for example, between the concentrations of D and ND in blood samples.</p>
</sec>
</sec>
<sec id="section6-0897190012451910">
<title>Results</title>
<sec id="section7-0897190012451910">
<title>Concentrations of D and ND in Blood</title>
<p>
<xref ref-type="table" rid="table1-0897190012451910">Table 1</xref> presents descriptive statistics mean, median, minimum, maximum, and upper percentiles for the concentrations of D and ND in blood from apprehended drivers. The correlation between concentrations of D and ND was statistically significant (<italic>r</italic> = .584, <italic>P</italic> &lt; .001).</p>
<table-wrap id="table1-0897190012451910" position="float">
<label>Table 1.</label>
<caption>
<p>Descriptive Statistics for Concentrations of Diazepam (D), Nordiazepam (ND) in Blood Samples From 1000 Apprehended Drivers.</p>
</caption>
<graphic alternate-form-of="table1-0897190012451910" xlink:href="10.1177_0897190012451910-table1.tif"/>
<table>
<thead>
<tr>
<th>Drugs </th>
<th>Mean (median) conc, mg/L</th>
<th>Min-max conc, mg/L</th>
<th colspan="4">Upper percentiles, mg/L</th>
</tr>
<tr>
<th>
</th>
<th>
</th>
<th>
</th>
<th>75th</th>
<th>90th</th>
<th>95th</th>
<th>99th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam (D)</td>
<td>0.374 (0.20)<sup>a</sup>
</td>
<td>0.05-6.1</td>
<td>0.4</td>
<td>0.8</td>
<td>1.2</td>
<td>2.4</td>
</tr>
<tr>
<td>Nordiazepam (ND)</td>
<td>0.388 (0.20)<sup>a</sup>
</td>
<td>0.05-5.6</td>
<td>0.5</td>
<td>0.8</td>
<td>1.2</td>
<td>2.8</td>
</tr>
<tr>
<td>Sum (D + ND)</td>
<td>0.763 (0.50)</td>
<td>0.11-7.6</td>
<td>0.9</td>
<td>1.7</td>
<td>2.3</td>
<td>5.1</td>
</tr>
<tr>
<td>Ratio D/ND</td>
<td>1.29 (0.95)</td>
<td>0.10-12.5</td>
<td>1.5</td>
<td>2.5</td>
<td>4.0</td>
<td>8.0</td>
</tr>
<tr>
<td>Ratio ND/D</td>
<td>1.41 (1.06)</td>
<td>0.08-10.0</td>
<td>1.9</td>
<td>2.5</td>
<td>3.5</td>
<td>6.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012451910">
<p>
<sup>a</sup> Pearson correlation coefficient between D and ND was <italic>r</italic> = .58 (<italic>P</italic> &lt; .001).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The relative frequency distributions of D and ND concentrations were similar in shape but both were positively skewed to the right as shown in <xref ref-type="fig" rid="fig1-0897190012451910">Figure 1</xref>. The mean, median, and range of concentrations of parent drug (D) and metabolite (ND) agreed well in both distributions having a median concentration of 0.02 mg/L.</p>
<fig id="fig1-0897190012451910" position="float">
<label>Figure 1.</label>
<caption>
<p>Relative frequency distributions of the concentrations of diazepam and nordiazepam in blood samples from 1000 impaired drivers. N = 17 cases (1.7%) having a concentration above 3.0 mg/L were not plotted for clarity.</p>
</caption>
<graphic xlink:href="10.1177_0897190012451910-fig1.tif"/>
</fig>
<p>D is not evenly distributed between plasma and whole blood and the plasma/blood ratio was found by experiment to be 1.8:1, depending in part on blood hematocrit.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012451910">16</xref>
</sup> This means that a plasma concentration of 1.5 mg/L, which is considered an upper therapeutic limit, corresponds to a concentration in whole blood of 0.83 mg/L (1.5/1.8 = 0.83). The frequency distributions in <xref ref-type="fig" rid="fig1-0897190012451910">Figure 1</xref> had N = 90 cases (9%) with a concentration of D above 0.83 mg/L.</p>
</sec>
<sec id="section8-0897190012451910">
<title>Sum of D and ND Concentration</title>
<p>Because both D and ND are pharmacologically active substances, the combined concentration (D + ND) might be more relevant when drug-related impairment is an issue. <xref ref-type="fig" rid="fig2-0897190012451910">Figure 2</xref> shows a relative frequency distribution of this total benzodiazepine concentrations (D + ND) in blood, which had N = 267 cases (27%) with a concentration above 0.83 mg/L.</p>
<fig id="fig2-0897190012451910" position="float">
<label>Figure 2.</label>
<caption>
<p>Relative frequency distribution of concentrations of diazepam (D) plus nordiazepam ([ND] sum of D and ND) in blood samples from 1000 impaired drivers. N = 29 cases (2.9%) having a concentration above 3 mg/L were not plotted for clarity.</p>
</caption>
<graphic xlink:href="10.1177_0897190012451910-fig2.tif"/>
</fig>
</sec>
<sec id="section9-0897190012451910">
<title>Concentration Ratios of D to ND</title>
<p>The concentration ratios of D/ND and ND/D are plotted in <xref ref-type="fig" rid="fig3-0897190012451910">Figure 3</xref> as relative frequency distributions. The mean D/ND ratio was 1.29 indicating more D than ND, but the median ratio was 0.95 showing roughly equal amounts of D and ND. The mean ratio of ND/D was 1.41 but the median was lower (1.06) and not significantly different from unity (<italic>P</italic> &gt; .05).</p>
<fig id="fig3-0897190012451910" position="float">
<label>Figure 3.</label>
<caption>
<p>Relative frequency distributions of concentration ratios of diazepam to nordiazepam (D/ND) left graph and ND/D (right graph). Cases with a concentration ratio &gt;6 were not plotted for clarity.</p>
</caption>
<graphic xlink:href="10.1177_0897190012451910-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-0897190012451910">
<title>Discussion</title>
<p>After its discovery in 1960s,<sup>
<xref ref-type="bibr" rid="bibr17-0897190012451910">17</xref>
</sup> the clinical pharmacokinetics of D after single acute doses<sup>
<xref ref-type="bibr" rid="bibr18-0897190012451910">18</xref>
</sup> as well as repetitive dosing<sup>
<xref ref-type="bibr" rid="bibr19-0897190012451910">19</xref>,<xref ref-type="bibr" rid="bibr20-0897190012451910">20</xref>
</sup> and after different routes of administration has been extensively studied. Moreover, the influence of age, gender, liver, and kidney functioning on pharmacokinetic profiles is also well documented.<sup>
<xref ref-type="bibr" rid="bibr21-0897190012451910">21</xref>
<xref ref-type="bibr" rid="bibr22-0897190012451910"/>–<xref ref-type="bibr" rid="bibr23-0897190012451910">23</xref>
</sup> The bioavailability of D after oral administration is close to 100% and the peak concentrations in plasma occur 30 to 60 minutes postdosing.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012451910">10</xref>
</sup> Both D and ND have long elimination half-lives and are, therefore, measurable in blood several days after the last dose is taken.<sup>
<xref ref-type="bibr" rid="bibr11-0897190012451910">11</xref>,<xref ref-type="bibr" rid="bibr21-0897190012451910">21</xref>,<xref ref-type="bibr" rid="bibr24-0897190012451910">24</xref>
</sup>
</p>
<p>In 48 healthy men, the mean (median) concentrations of D in plasma after a 10-mg oral dose were 0.406 mg/L (0.403 mg/L).<sup>
<xref ref-type="bibr" rid="bibr21-0897190012451910">21</xref>
</sup> These plasma concentrations are equivalent to 0.335 mg/L (0.323 mg/L) in whole blood, assuming a plasma/blood distribution ratio of 1.8:1.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012451910">16</xref>
</sup> During long-term D therapy (1-14 years), the steady-sate concentrations of D and ND in plasma were 0.329 mg/L (0.183 mg/L blood) and 0.389 mg/L (0.216 mg/L blood), respectively. Moreover, in this chronic dosing study, the metabolite and parent drug concentrations were highly correlated (<italic>r</italic> = .80) and the concentration ratio ND/D was 1.26.<sup>
<xref ref-type="bibr" rid="bibr11-0897190012451910">11</xref>
</sup>
</p>
<p>In the present study, the mean (0.374 mg/L) and median (0.20 mg/L) concentrations of D in blood of 1000 apprehended drivers agreed well with the concentrations determined in various clinical studies with this anxiolytic drug. This suggests that the average driver in Sweden used D medication properly.</p>
<p>Although use of benzodiazepines before driving increases the risk of a traffic crash,<sup>
<xref ref-type="bibr" rid="bibr25-0897190012451910">25</xref>
</sup> there was only a weak association between the concentration of D in blood and results of clinical tests of impairment.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012451910">7</xref>,<xref ref-type="bibr" rid="bibr26-0897190012451910">26</xref>
</sup> Because both D and ND are pharmacologically active substances, this makes it reasonable to add the concentrations together when traffic cases are interpreted in terms of likely drug-related impairment. The risk of a crash after medication with D is more pronounced during the first few days rather than after several weeks of treatment, when steady-state concentration in plasma are reached and tolerance to the drug has developed.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012451910">27</xref>,<xref ref-type="bibr" rid="bibr28-0897190012451910">28</xref>
</sup> In this connection, care is needed when theraeutic drug concentrations are interreted because people suffering from an anxiety or neurological disorder and taking a benzodiazepine might be more of a danger for traffic safety without their medication than after therapeutic usage.<sup>
<xref ref-type="bibr" rid="bibr29-0897190012451910">29</xref>
</sup>
</p>
<p>Sedative-hypnotic drugs are often subjected to abuse, as exemplified by barbiturates, benzodiazepines, and ethanol.<sup>
<xref ref-type="bibr" rid="bibr30-0897190012451910">30</xref>
<xref ref-type="bibr" rid="bibr31-0897190012451910"/>–<xref ref-type="bibr" rid="bibr32-0897190012451910">32</xref>
</sup> These substances impair both cognitive and psychomotor functioning and should not be used when skilled tasks, such as driving a motor vehicle are performed.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012451910">7</xref>,<xref ref-type="bibr" rid="bibr33-0897190012451910">33</xref>
<xref ref-type="bibr" rid="bibr34-0897190012451910"/>–<xref ref-type="bibr" rid="bibr35-0897190012451910">35</xref>
</sup> Moreover, the combined use of D and ethanol is likely to represent a bigger problem for traffic safety than either drug alone, because both work by binding to the GABA<sub>A</sub> receptor complex to cause sedation by slowing brain activity.<sup>
<xref ref-type="bibr" rid="bibr36-0897190012451910">36</xref>
<xref ref-type="bibr" rid="bibr37-0897190012451910"/>–<xref ref-type="bibr" rid="bibr38-0897190012451910">38</xref>
</sup>
</p>
<p>The relative danger of D and ethanol for driving is difficult to compare because the pharmacokinetic profiles are so different. This includes dose–effect relationship, frequency of intake, degree of protein binding, plasma–blood distribution ratio, and tolerance development, which are very different. This makes it difficult to defend the creation of a punishable concentration of D in blood, which recently happened in Norway. In this country, a blood concentration of D of 0.342 mg/L is considered equivalent to a blood–ethanol concentrations of 1.12 g/L (0.12 g%), which might surprise traffic safety experts and clinical pharmacologists.<sup>
<xref ref-type="bibr" rid="bibr39-0897190012451910">39</xref>,<xref ref-type="bibr" rid="bibr40-0897190012451910">40</xref>
</sup> The optimal therapeutic concentration of D depends on a person’s age, clinical diagnosis, and how long the medication has been taken.</p>
<p>When therapeutic concentrations of drugs in plasma or serum are compared with the levels found in forensic toxicology (impaired drivers and medical examiner cases), it is important to consider the plasma/blood distribution ratio. Because D is highly bound to plasma proteins (∼99%),<sup>
<xref ref-type="bibr" rid="bibr41-0897190012451910">41</xref>
</sup> its distribution between plasma and whole blood is greater than unity and was found to be 1.8:1, depending in part on hematocrit.<sup>
<xref ref-type="bibr" rid="bibr16-0897190012451910">16</xref>,<xref ref-type="bibr" rid="bibr42-0897190012451910">42</xref>
</sup> The accepted therapeutic concentration of D in serum or plasma is in the range 0.2 to 1.5 mg/L, which corresponds to 0.11 to 0.83 mg/L in whole blood (plasma/blood ratio 1.8). Accordingly, if the concentration of D in forensic blood samples exceeds 0.83 mg/L, this suggests overdosing or abuse of the medication. However, in individual cases, one might also consider polymorphic hepatic enzymes and slow drug metabolizers or even protein-binding interactions as possible explanations for supratherapeutic concentrations of D.</p>
<p>Impaired drivers are often poly-drug users, who might take an illicit recreational drug as well as one or more prescription drugs.<sup>
<xref ref-type="bibr" rid="bibr43-0897190012451910">43</xref>
</sup> Under a zero-tolerance law, an impaired-driving charge is brought with any measurable amount of an illicit drug in blood, although for scheduled prescription drugs additional evidence is necessary.<sup>
<xref ref-type="bibr" rid="bibr44-0897190012451910">44</xref>
</sup> The analytical threshold concentration of D in blood in Denmark is 0.02 mg/L, although this only applies if the driver lacks a valid prescription for the medication. In Sweden, the threshold concentration for reporting positive results is 0.05 mg/L, but a prosecution for DUID requires that the concentration of D in blood exceeds 0.83 mg/L (&gt;1.5 mg/L in plasma).<sup>
<xref ref-type="bibr" rid="bibr45-0897190012451910">45</xref>
</sup>
</p>
<p>In conclusion, most apprehended drivers with D and ND in blood samples used their anxiolytic medication properly. However, there were 90 cases (9%) for whom the concentration of D was above 0.83 mg/L (1.5 mg/L in plasma), which suggests overdosing or abuse of the medication. When considering the concentrations of D plus ND, there were 267 cases (27%) above the upper threshold of 0.83 mg/L.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012451910">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012451910">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012451910">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>AW</given-names>
</name>
</person-group>. <article-title>Driving under the influence of drugs in Sweden with zero concentration limits in blood for controlled substances</article-title>. <source>Traffic Inj Prev</source>. <year>2005</year>;<volume>6</volume>(<issue>4</issue>):<fpage>317</fpage>–<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012451910">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ojaniemi</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Lintonen</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Impinen</surname>
<given-names>AO</given-names>
</name>
<etal/>
</person-group> <article-title>Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977-2007</article-title>. <source>Accid Anal Prev</source>. <year>2009</year>;<volume>41</volume>(<issue>1</issue>):<fpage>191</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012451910">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steentoft</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simonsen</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Linnet</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>The frequency of drugs among Danish drivers before and after the introduction of fixed concentration limits</article-title>. <source>Traffic Inj Prev</source>. <year>2010</year>;<volume>11</volume>(<issue>4</issue>):<fpage>329</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012451910">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christophersen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Morland</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Frequent detection of benzodiazepines in drugged drivers in Norway</article-title>. <source>Traffic Inj Prev</source>. <year>2008</year>;<volume>9</volume>(<issue>2</issue>):<fpage>98</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012451910">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steentoft</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simonsen</surname>
<given-names>KW</given-names>
</name>
<etal/>
</person-group> <article-title>Drugs related to motor vehicle crashes in northern European countries: A study of fatally injured drivers</article-title>. <source>Accid Anal Prev</source>. <year>2011</year>;<volume>43</volume>(<issue>6</issue>):<fpage>1920</fpage>–<lpage>1926</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012451910">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skurtveit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abotnes</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Christophersen</surname>
<given-names>AS</given-names>
</name>
</person-group>. <article-title>Drugged drivers in Norway with benzodiazepine detections</article-title>. <source>Forensic Sci Int</source>. <year>2002</year>;<volume>125</volume>(<issue>1</issue>):<fpage>75</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012451910">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bramness</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Skurtveit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morland</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Clinical impairment of benzodiazepines—relation between benzodiazepine concentrations and impairment in apprehended drivers</article-title>. <source>Drug Alcohol Depend</source>. <year>2002</year>;<volume>68</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012451910">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Verstraete</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Huestis</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group> <article-title>Guidelines for research on drugged driving</article-title>. <source>Addiction</source>. <year>2008</year>;<volume>103</volume>(<issue>8</issue>):<fpage>1258</fpage>–<lpage>1268</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012451910">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blencowe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Raaska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lillsunde</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Benzodiazepines and sedative-hypnotics in blood of drivers under the influence and their association with other common illegal drug use and national sales figures</article-title>. <source>Ther Drug Monit</source>. <year>2011</year>;<volume>33</volume>(<issue>1</issue>):<fpage>64</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012451910">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Harmatz</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group> <article-title>Diazepam disposition determinants</article-title>. <source>Clin Pharmacol Ther</source>. <year>1980</year>;<volume>27</volume>(<issue>3</issue>):<fpage>301</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012451910">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Laughren</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group> <article-title>Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy</article-title>. <source>Br J Clin Pharmacol</source>. <year>1981</year>;<volume>11</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012451910">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Winger</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Abuse liability of benzodiazepines</article-title>. <source>Pharmacol Rev</source>. <year>1987</year>;<volume>39</volume>(<issue>4</issue>):<fpage>251</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012451910">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smink</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Egberts</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lusthof</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group> <article-title>The relationship between benzodiazepine use and traffic accidents: a systematic literature review</article-title>. <source>CNS Drugs</source>. <year>2010</year>;<volume>24</volume>(<issue>8</issue>):<fpage>639</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012451910">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Divoll</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Soong</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group> <article-title>Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam</article-title>. <source>J Clin Pharmacol</source>. <year>1988</year>;<volume>28</volume>(<issue>9</issue>):<fpage>853</fpage>–<lpage>859</lpage>.</citation>
</ref>
<ref id="bibr15-0897190012451910">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochs</surname>
<given-names>HR.</given-names>
</name>
</person-group> <article-title>Benzodiazepine: Bedeutung der Kinetik für die Therapie</article-title>. <source>Klin Wochenschr</source>. <year>1983</year>;<volume>61</volume>(<issue>5</issue>):<fpage>213</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012451910">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Distribution of diazepam and nordiazepam between plasma and whole blood and the influence of hematocrit</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>(<issue>4</issue>):<fpage>380</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012451910">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sternbach</surname>
<given-names>LH</given-names>
</name>
</person-group>. <article-title>The benzodiazepine story</article-title>. <source>J Psychoactive Drugs</source>. <year>1983</year>;<volume>15</volume>(<issue>1-2</issue>):<fpage>15</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012451910">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time</article-title>. <source>Clin Pharmacol Ther</source>. <year>1992</year>;<volume>52</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012451910">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutherford</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Okoko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tyrer</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy</article-title>. <source>Br J Clin Pharmacol</source>. <year>1978</year>;<volume>6</volume>(<issue>1</issue>):<fpage>69</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012451910">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollister</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>RH</given-names>
</name>
<etal/>
</person-group> <article-title>Long-term use of diazepam</article-title>. <source>JAMA</source>. <year>1981</year>;<volume>246</volume>(<issue>14</issue>):<fpage>1568</fpage>–<lpage>1570</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012451910">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Harmatz</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>A large-sample study of diazepam pharmacokinetics</article-title>. <source>Ther Drug Monit</source>. <year>1989</year>;<volume>11</volume>(<issue>6</issue>):<fpage>652</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012451910">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Harmatz</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Shader</surname>
<given-names>RI</given-names>
</name>
</person-group>. <article-title>Factors influencing diazepam pharmacokinetics: age, sex, and liver disease</article-title>. <source>Int J Clin Pharmacol Biopharm</source>. <year>1978</year>;<volume>16</volume>(<issue>4</issue>):<fpage>177</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012451910">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Antonin</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Brugel</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease</article-title>. <source>Clin Pharmacol Ther</source>. <year>1977</year>;<volume>21</volume>(<issue>4</issue>):<fpage>430</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012451910">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abernethy</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Divoll</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate)</article-title>. <source>J Pharm Sci</source>. <year>1982</year>;<volume>71</volume>(<issue>8</issue>):<fpage>942</fpage>–<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012451910">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Davey</surname>
<given-names>PG</given-names>
</name>
<etal/>
</person-group> <article-title>Association of road-traffic accidents with benzodiazepine use</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>352</volume>(<issue>9137</issue>):<fpage>1331</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012451910">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuitunen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Meririnne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Seppala</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Correlation between blood diazepam concentrations and performance on clinical tests for drunkenness in acute and chronic users</article-title>. <source>J Traffic Med</source>. <year>1994</year>;<volume>22</volume>:<fpage>105</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012451910">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smink</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Lusthof</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>de Gier</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group> <article-title>The relation between the blood benzodiazepine concentration and performance in suspected impaired drivers</article-title>. <source>J Forensic Leg Med</source>. <year>2008</year>;<volume>15</volume>(<issue>8</issue>):<fpage>483</fpage>–<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012451910">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neutel</surname>
<given-names>CI</given-names>
</name>
</person-group>. <article-title>Risk of traffic accident injury after a prescription for a benzodiazepine</article-title>. <source>Ann Epidemiol</source>. <year>1995</year>;<volume>5</volume>(<issue>3</issue>):<fpage>239</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012451910">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neutel</surname>
<given-names>CI</given-names>
</name>
</person-group>. <article-title>The epidemiology of long-term benzodiazepine use</article-title>. <source>Int Rev Psychiatry</source>. <year>2005</year>;<volume>17</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012451910">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>Use and abuse of the benzodiazepines</article-title>. <source>Ther Drug Monit</source>. <year>1998</year>;<volume>20</volume>(<issue>5</issue>):<fpage>481</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012451910">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Impinen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rahkonen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Karjalainen</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Substance use as a predictor of driving under the influence (DUI) rearrests. a 15-year retrospective study</article-title>. <source>Traffic Inj Prev</source>. <year>2009</year>;<volume>10</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012451910">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lader</surname>
<given-names>MH.</given-names>
</name>
</person-group> <article-title>Abuse and dependence on the benzodiazepines</article-title>. <source>Clin Neuropharmacol</source>. <year>1992</year>;<volume>15</volume>(<issue>suppl 1 Pt A</issue>):<fpage>106A</fpage>–<lpage>107A</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012451910">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gustavsen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Al-Sammurraie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morland</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers</article-title>. <source>Accid Anal Prev</source>. <year>2009</year>;<volume>41</volume>(<issue>3</issue>):<fpage>462</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012451910">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mattila</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Acute and subacute effects of diazepam on human performance: comparison of plain tablet and controlled release capsule</article-title>. <source>Pharmacol Toxicol</source>. <year>1988</year>;<volume>63</volume>(<issue>5</issue>):<fpage>369</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr35-0897190012451910">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mets</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Volkerts</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of hypnotic drugs on body balance and standing steadiness</article-title>. <source>Sleep Med Rev</source>. <year>2010</year>;<volume>14</volume>(<issue>4</issue>):<fpage>259</fpage>–<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012451910">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingum</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bjorklund</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bjorneboe</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1992</year>;<volume>107</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012451910">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aranko</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seppala</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pellinen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Interaction of diazepam or lorazepam with alcohol. Psychomotor effects and bioassayed serum levels after single and repeated doses</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1985</year>;<volume>28</volume>(<issue>5</issue>):<fpage>559</fpage>–<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012451910">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linnoila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mattila</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kitchell</surname>
<given-names>BS</given-names>
</name>
</person-group>. <article-title>Drug interactions with alcohol</article-title>. <source>Drugs</source>. <year>1979</year>;<volume>18</volume>(<issue>4</issue>):<fpage>299</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr39-0897190012451910">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gjerde</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Normann</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Christophersen</surname>
<given-names>AS</given-names>
</name>
<etal/>
</person-group> <article-title>Prevalence of driving with blood drug concentrations above proposed new legal limits in Norway: Estimations based on drug concentrations in oral fluid</article-title>. <source>Forensic Sci Int</source>. <year>2011</year>;<volume>210</volume>(<issue>1-3</issue>):<fpage>221</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012451910">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vindenes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jordbru</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Knapskog</surname>
<given-names>AB</given-names>
</name>
<etal/>
</person-group> <article-title>Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway</article-title>. <source>Forensic Sci Int</source>. <year>2012</year>;<volume>219</volume>(<issue>1-3</issue>):<fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012451910">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divoll</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Binding of diazepam and desmethyldiazepam to plasma protein: concentration-dependence and interactions</article-title>. <source>Psychopharmacology (Berl)</source>. <year>1981</year>;<volume>75</volume>(<issue>4</issue>):<fpage>380</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012451910">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Distribution of diazepam between plasma and whole blood</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>(<issue>6</issue>):<fpage>693</fpage>.</citation>
</ref>
<ref id="bibr43-0897190012451910">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmgren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kugelberg</surname>
<given-names>FC</given-names>
</name>
<etal/>
</person-group> <article-title>Predominance of illicit drugs and poly-drug use among drug-impaired drivers in Sweden</article-title>. <source>Traffic Inj Prev</source>. <year>2007</year>;<volume>8</volume>(<issue>4</issue>):<fpage>361</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012451910">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmgren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kugelberg</surname>
<given-names>FC</given-names>
</name>
<etal/>
</person-group> <article-title>High re-arrest rates among drug-impaired drivers despite zero-tolerance legislation</article-title>. <source>Accid Anal Prev</source>. <year>2008</year>;<volume>40</volume>(<issue>2</issue>):<fpage>534</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012451910">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kugelberg</surname>
<given-names>FC</given-names>
</name>
</person-group>. <article-title>Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results</article-title>. <source>Ther Drug Monit</source>. <year>2007</year>;<volume>29</volume>(<issue>2</issue>):<fpage>248</fpage>–<lpage>260</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>